$52.58
Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alkermes to Report Second Quarter Financial Results on July 28, 2026
Alkermes Public's Alixorexton Demonstrates Durable Efficacy in Narcolepsy Patients
Overview
52-week range
$25
$44
100% of range
Avg surprise (last 3)
+25.1%
Avg reaction (last 2)
+6.2%
100% positive
Latest IV / EM
53%
EM ±12.2% · $55 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.40 | $-0.57 | +29.8% | -407.7% | +6.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.49 | — | — | — | — | financials |
| Tue Jul 29, 2025 | Jun/2025 | $0.52 | $0.30 | +73.3% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $0.13 | $0.18 | -27.8% | — | +6.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.55 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.53 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.21 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.28 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $1.38 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Jul 28, 2026 | Jun/2026 | BMO | -$0.04 | $0.52 | -107.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $393M | — | $394M | $391M | $307M | — | $378M | $399M |
| Cost of revenue | $62M | — | $52M | $49M | $49M | — | $63M | $61M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-48M | — | $89M | $93M | $14M | — | $105M | $110M |
| Net income | $-66M | — | $83M | $87M | $22M | — | $92M | $91M |
| EPS (diluted) | $-0.40 | — | $0.49 | $0.52 | $0.13 | — | $0.55 | $0.53 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $352M | $389M | $616M | $521M | $400M | $291M | $396M | $535M |
| Inventory | $337M | $197M | $191M | $192M | $183M | $183M | $191M | $195M |
| Total current assets | $1.36B | $1.93B | $1.74B | $1.64B | $1.48B | $1.42B | $1.56B | $1.54B |
| Total assets | $4.26B | $2.49B | $2.33B | $2.25B | $2.08B | $2.06B | $2.16B | $2.21B |
| Long-term debt | $1.48B | $0 | — | — | — | — | $286M | $286M |
| Total liabilities | $2.51B | $668M | $596M | $628M | $570M | $591M | $863M | $923M |
| Total equity | $1.75B | $1.82B | $1.73B | $1.62B | $1.51B | $1.46B | $1.29B | $1.28B |